APO Research
Talk to an analyst

APO RESEARCH · REPORT

Resistant Pseudomonas Aeruginosa Infections Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Analysis and Forecast 2026-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchResistant Pseudomonas Aeruginosa Infections Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Resistant Pseudomonas Aeruginosa Infections Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Resistant Pseudomonas Aeruginosa Infections Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Resistant Pseudomonas Aeruginosa Infections Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Resistant Pseudomonas Aeruginosa Infections Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Resistant Pseudomonas Aeruginosa Infections Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include Achaogen Inc, AmpliPhi Biosciences Corp, Biolytics Pharma, ContraFect Corp, Inhibrx LP, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Shionogi & Co Ltd and Novartis AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Resistant Pseudomonas Aeruginosa Infections Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Resistant Pseudomonas Aeruginosa Infections Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Resistant Pseudomonas Aeruginosa Infections Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Resistant Pseudomonas Aeruginosa Infections Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Resistant Pseudomonas Aeruginosa Infections Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Resistant Pseudomonas Aeruginosa Infections Drugs sales, projected growth trends, production technology, application and end-user industry.

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Company

Achaogen Inc

AmpliPhi Biosciences Corp

Biolytics Pharma

ContraFect Corp

Inhibrx LP

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Shionogi & Co Ltd

Novartis AG

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type

Cephalosporin

Lactam Drugs

Semi-Synthetic Penicillin

Others

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application

Hospital

Clinic

Home Care

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Resistant Pseudomonas Aeruginosa Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Resistant Pseudomonas Aeruginosa Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Resistant Pseudomonas Aeruginosa Infections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Resistant Pseudomonas Aeruginosa Infections Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Resistant Pseudomonas Aeruginosa Infections Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cephalosporin Major Manufacturers Table 3. Lactam Drugs Major Manufacturers Table 4. Semi-Synthetic Penicillin Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Home Care Major Manufacturers Table 10. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends Table 11. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers Table 12. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges Table 13. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints Table 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2021-2026) Table 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2027-2032) Table 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers, Product Type & Application Table 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2026) Table 44. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2027-2032) Table 45. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2026) Table 56. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2027-2032) Table 57. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Achaogen Inc Company Information Table 60. Achaogen Inc Business Overview Table 61. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 63. Achaogen Inc Recent Development Table 64. AmpliPhi Biosciences Corp Company Information Table 65. AmpliPhi Biosciences Corp Business Overview Table 66. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 68. AmpliPhi Biosciences Corp Recent Development Table 69. Biolytics Pharma Company Information Table 70. Biolytics Pharma Business Overview Table 71. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 73. Biolytics Pharma Recent Development Table 74. ContraFect Corp Company Information Table 75. ContraFect Corp Business Overview Table 76. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 78. ContraFect Corp Recent Development Table 79. Inhibrx LP Company Information Table 80. Inhibrx LP Business Overview Table 81. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 83. Inhibrx LP Recent Development Table 84. LegoChem Biosciences Inc Company Information Table 85. LegoChem Biosciences Inc Business Overview Table 86. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 88. LegoChem Biosciences Inc Recent Development Table 89. Melinta Therapeutics Inc Company Information Table 90. Melinta Therapeutics Inc Business Overview Table 91. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 93. Melinta Therapeutics Inc Recent Development Table 94. Shionogi & Co Ltd Company Information Table 95. Shionogi & Co Ltd Business Overview Table 96. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 98. Shionogi & Co Ltd Recent Development Table 99. Novartis AG Company Information Table 100. Novartis AG Business Overview Table 101. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 103. Novartis AG Recent Development Table 104. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 105. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 106. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 107. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 108. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 109. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 110. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 113. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 114. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 115. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 116. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 118. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 119. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 120. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 121. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 122. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 123. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 124. United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 125. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 126. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 127. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 128. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 129. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 130. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 131. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 132. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 133. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 134. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 135. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 136. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 137. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 138. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 142. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 143. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 144. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 145. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 146. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 147. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 148. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 149. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 150. Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 151. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 152. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 153. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 154. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 155. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 156. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 157. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 158. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 159. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 160. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 161. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 162. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 163. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 166. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 167. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 168. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 169. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 170. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 172. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 173. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 174. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 175. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 179. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 180. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 181. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 182. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 183. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 184. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 185. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 186. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 187. China Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 189. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 192. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 193. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 194. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 195. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 196. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 197. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 198. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 199. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 200. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 201. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 205. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 206. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 207. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 208. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 209. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 210. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 211. Chile Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 212. Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 213. Peru Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 215. Israel Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 216. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 217. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 218. Iran Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 219. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List Table 223. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Image Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cephalosporin Image Figure 5. Lactam Drugs Image Figure 6. Semi-Synthetic Penicillin Image Figure 7. Others Image Figure 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Home Care Image Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2021-2032) & (K Units) Figure 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2032) Figure 42. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2032) Figure 43. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2032) Figure 44. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2032) Figure 45. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country (2021-2032) Figure 46. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Country (2021-2032) Figure 47. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2032) Figure 49. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2032) Figure 51. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Country (2021-2032) Figure 53. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2032) Figure 54. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2032) Figure 55. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2032) Figure 56. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2032) Figure 57. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2032) Figure 59. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2032) Figure 61. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Country (2021-2032) Figure 69. Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Cephalosporin
  • Lactam Drugs
  • Semi-Synthetic Penicillin
  • Others
Applications
  • Hospital
  • Clinic
  • Home Care
Companies covered
  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Shionogi & Co Ltd
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Type
  3. 1.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cephalosporin
  5. 1.2.3 Lactam Drugs
  6. 1.2.4 Semi-Synthetic Penicillin
  7. 1.2.5 Others
  8. 1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application
  9. 1.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Home Care
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Dynamics
  1. 2.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends
  2. 2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers
  3. 2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges
  4. 2.4 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region
  3. 3.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region
  9. 3.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers
  2. 4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers
  6. 4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market CR5 and HHI
  16. 4.8.2 2025 Resistant Pseudomonas Aeruginosa Infections Drugs Tier 1, Tier 2, and Tier 3
5 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Type
  1. 5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type
  2. 5.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type
  6. 5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type
6 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application
  1. 6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application
  2. 6.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application
  6. 6.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application
7 Company Profiles
  1. 7.1 Achaogen Inc
  2. 7.1.1 Achaogen Inc Company Information
  3. 7.1.2 Achaogen Inc Business Overview
  4. 7.1.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  6. 7.1.5 Achaogen Inc Recent Developments
  7. 7.2 AmpliPhi Biosciences Corp
  8. 7.2.1 AmpliPhi Biosciences Corp Company Information
  9. 7.2.2 AmpliPhi Biosciences Corp Business Overview
  10. 7.2.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  12. 7.2.5 AmpliPhi Biosciences Corp Recent Developments
  13. 7.3 Biolytics Pharma
  14. 7.3.1 Biolytics Pharma Company Information
  15. 7.3.2 Biolytics Pharma Business Overview
  16. 7.3.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  18. 7.3.5 Biolytics Pharma Recent Developments
  19. 7.4 ContraFect Corp
  20. 7.4.1 ContraFect Corp Company Information
  21. 7.4.2 ContraFect Corp Business Overview
  22. 7.4.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  24. 7.4.5 ContraFect Corp Recent Developments
  25. 7.5 Inhibrx LP
  26. 7.5.1 Inhibrx LP Company Information
  27. 7.5.2 Inhibrx LP Business Overview
  28. 7.5.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  30. 7.5.5 Inhibrx LP Recent Developments
  31. 7.6 LegoChem Biosciences Inc
  32. 7.6.1 LegoChem Biosciences Inc Company Information
  33. 7.6.2 LegoChem Biosciences Inc Business Overview
  34. 7.6.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  36. 7.6.5 LegoChem Biosciences Inc Recent Developments
  37. 7.7 Melinta Therapeutics Inc
  38. 7.7.1 Melinta Therapeutics Inc Company Information
  39. 7.7.2 Melinta Therapeutics Inc Business Overview
  40. 7.7.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  42. 7.7.5 Melinta Therapeutics Inc Recent Developments
  43. 7.8 Shionogi & Co Ltd
  44. 7.8.1 Shionogi & Co Ltd Company Information
  45. 7.8.2 Shionogi & Co Ltd Business Overview
  46. 7.8.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  48. 7.8.5 Shionogi & Co Ltd Recent Developments
  49. 7.9 Novartis AG
  50. 7.9.1 Novartis AG Company Information
  51. 7.9.2 Novartis AG Business Overview
  52. 7.9.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  54. 7.9.5 Novartis AG Recent Developments
8 North America
  1. 8.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type
  2. 8.1.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
  5. 8.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application
  6. 8.2.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
  9. 8.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
  10. 8.3.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type
  2. 9.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
  5. 9.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application
  6. 9.2.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
  9. 9.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
  10. 9.3.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type
  2. 10.1.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
  5. 10.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application
  6. 10.2.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type
  2. 11.1.1 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
  5. 11.2 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application
  6. 11.2.1 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
  9. 11.3 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
  10. 11.3.1 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Resistant Pseudomonas Aeruginosa Infections Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type
  2. 12.1.1 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application
  6. 12.2.1 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
  10. 12.3.1 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Analysis
  2. 13.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process
  6. 13.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors
  9. 13.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst